niclosamide has been researched along with Androgen-Independent Prostatic Cancer in 10 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide has preclinical activity against a wide range of cancers." | 3.01 | Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. ( Agarwal, N; Dall'Era, M; Evans, CP; Gao, AC; Lara, PN; Liu, C; Pan, CX; Parikh, M; Robles, D; Wu, CY, 2021) |
| "Niclosamide was given three-times-daily (TID) at the following dose-levels: 500, 1000 or 1500mg." | 2.87 | A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. ( Cheng, HH; Dumpit, RF; Gulati, R; Haugk, K; Maes, JL; McCune, JS; McKiernan, JS; Montgomery, B; Nelson, PS; Plymate, SR; Schweizer, MT; Yu, EY, 2018) |
| "Niclosamide was identified as a novel inhibitor of AR variants." | 1.40 | Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. ( Evans, CP; Gao, AC; Liu, C; Lou, W; Nadiminty, N; Schwartz, CT; Zhu, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakellakis, M | 1 |
| Parikh, M | 1 |
| Liu, C | 3 |
| Wu, CY | 1 |
| Evans, CP | 2 |
| Dall'Era, M | 1 |
| Robles, D | 1 |
| Lara, PN | 1 |
| Agarwal, N | 1 |
| Gao, AC | 3 |
| Pan, CX | 1 |
| Sobhani, N | 2 |
| Neeli, PK | 1 |
| D'Angelo, A | 2 |
| Pittacolo, M | 1 |
| Sirico, M | 1 |
| Galli, IC | 1 |
| Roviello, G | 2 |
| Nesi, G | 1 |
| Schweizer, MT | 1 |
| Haugk, K | 1 |
| McKiernan, JS | 1 |
| Gulati, R | 1 |
| Cheng, HH | 1 |
| Maes, JL | 1 |
| Dumpit, RF | 1 |
| Nelson, PS | 1 |
| Montgomery, B | 1 |
| McCune, JS | 1 |
| Plymate, SR | 1 |
| Yu, EY | 1 |
| Generali, D | 1 |
| Aieta, M | 1 |
| Wach, S | 1 |
| Taubert, H | 1 |
| Cronauer, M | 1 |
| Lou, W | 2 |
| Zhu, Y | 2 |
| Nadiminty, N | 1 |
| Schwartz, CT | 1 |
| Fenner, A | 1 |
| Armstrong, C | 1 |
| Ippolito, JE | 1 |
| Brandenburg, MW | 1 |
| Ge, X | 1 |
| Crowley, JR | 1 |
| Kirmess, KM | 1 |
| Som, A | 1 |
| D'Avignon, DA | 1 |
| Arbeit, JM | 1 |
| Achilefu, S | 1 |
| Yarasheski, KE | 1 |
| Milbrandt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer[NCT02532114] | Phase 1 | 5 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niclosamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.
Topics: Alternative Splicing; Androgen Receptor Antagonists; Humans; Male; Mutation; Niclosamide; Prostatic | 2021 |
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.
Topics: Alternative Splicing; Clinical Trials as Topic; Humans; Male; Models, Biological; Niclosamide; Prost | 2018 |
Role of androgen receptor splice variants, their clinical relevance and treatment options.
Topics: Alternative Splicing; Androgen Antagonists; Androstadienes; Antineoplastic Agents, Hormonal; Benzami | 2020 |
2 trials available for niclosamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Relat | 2021 |
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferat | 2018 |
5 other studies available for niclosamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Niclosamide in prostate cancer: An inhibitor of AR-V7, a mitochondrial uncoupler, or more?
Topics: Antineoplastic Agents; Humans; Male; Niclosamide; Prostatic Neoplasms, Castration-Resistant; Recepto | 2023 |
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Chromat | 2014 |
Prostate cancer: Niclosamide jumps the hurdle of enzalutamide resistance.
Topics: Androgen Antagonists; Animals; Drug Resistance, Neoplasm; Humans; Male; Niclosamide; Phenylthiohydan | 2014 |
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2016 |
Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.
Topics: Acids; Cell Line, Tumor; Energy Metabolism; Glucose; Glycolysis; Humans; Hydrogen-Ion Concentration; | 2016 |